Obama Thinks "Precision Medicine" Will Make Us Healthier. Experts are Skeptical.
By Julia Belluz,
Vox
| 01. 30. 2015
Untitled Document
The White House is committing $215 million to support efforts to develop personalized medicine, a priority the President touched on in his State of the Union earlier this month.
At the time, the details weren't clear. But today the White House released more information on the "precision medicine initiative," which has bipartisan support: it would get started with a $215 million cash injection from the 2016 federal budget to support everything from the building databases at the National Institutes of Health to study the genetic bases of disease, to applying that knowledge to targeted cancer therapeutics and public health.
"Most medical treatments have been designed for the 'average patient,'" the White House statement read. "As a result of this 'one-size-fits-all-approach,' treatments can be very successful for some patients but not for others."
The only problem is that this is much, much harder than it sounds.
Precision medicine — also known as personalized or individualized medicine — has been one of the big, unmet promises in health care for a long time. Hank Greely, a law professor at Stanford...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...